Science and Research

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

To characterize the effect of bexotegrast
versus placebo on the change in FVC in
participants with idiopathic pulmonary
fibrosis (IPF) at Week 52

Study details
Study-ID: 2023-506185-31-00
Study-ID: 2023-506185-31-00
DZL Disease Area: DPLD
DZL Disease Area: DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: BREATH
DZL Participating Sites: BREATH
Start Date: 28.08.2024
Completion Date: 28.02.2025
Status: Closed
Status: Closed
DZL recruiting center


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.